Navigation Links
Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
Date:3/10/2008

th new HIV drugs approved by the FDA in 2007," said Bill Young, Monogram's chief executive officer. "We are delighted to work with Avexa on their exciting development programs, and to build international partnerships that bring truly global cooperation and innovation to the fight against HIV."

As recommended by the U.S. FDA Antiviral Drugs Advisory Committee, biopharmaceutical companies are using HIV resistance testing technology to support and enhance next-generation HIV drug development. Monogram's proprietary technology is being applied to new HIV drug targets for screening and in subsequent clinical development programs for optimization of background therapy, patient monitoring and, in the case of CCR5 antagonists, for patient selection.

About Monogram

Monogram is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

About Avexa

Avexa Limited is a Melbourne, Australia-based biotechnology company with a focus on research and development of drugs for the treatment of infectious diseases. Avexa has dedicated resources and funding for key projects including its HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections. The Company's lead program is apricitabine (ATC), an anti-HIV drug which has successfully completed the 48 week dosing of its Phase 2b trial and has
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
2. Monogram Biosciences to Present at the ThinkEquity Partners Fifth Annual Growth Conference
3. Monogram Biosciences to Present at the JMP Securities Healthcare Conference
4. Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call
5. Monogram Announces Third Quarter 2007 Financial Results
6. Monogram Biosciences to Present at the Piper Jaffray 19th Annual Healthcare Conference
7. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
8. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
11. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Cambridge, MA & Budapest, Hungary (PRWEB) April 30, ... the only web-based electronic lab notebook with integrated ... leader in providing chemistry software solutions and consulting ... that led to the development of Labguru’s newest ... a set of deep domain features for biologists, ...
(Date:4/30/2015)... April 30, 2015 - ... Biotechnology Company   Shire (LSE: SHP, ... three months to March 31, 2015. ... million +9% +13% Total revenues $1,488 million +11% +15% ... GAAP operating income from continuing operations $475 million +55% ...
(Date:4/30/2015)... April 30, 2015 SureClinical, a leader ... I. Morris has joined SureClinical’s executive team as Chief ... biotech and technology executive with over 25 years in ... companies. , Ms. Morris joins SureClinical from Marrone ... She was CFO of MBI from its founding in ...
(Date:4/29/2015)... Washington, and BALTIMORE, Maryland, USA (PRWEB) April 29, 2015 ... event for photonics, optical sensing, and imaging on the ... place for government program managers, researchers, applications developers, and ... technology of sensing and imaging for multiple applications. , ... defense and security, and commercial and scientific sensing and ...
Breaking Biology Technology:Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 2Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 3Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 4Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 6Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 7Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 8Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 9Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 10Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 11Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 12Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 13Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 14Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 15Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 16Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 17Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 18Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 19Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 20Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 21Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 22Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 23Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 24Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 25Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 26Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 27Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 28Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 29Julie I. Morris Joins SureClinical as Chief Financial Officer 2SPIE DSS provides venue for collaboration vital to research, applications advances 2SPIE DSS provides venue for collaboration vital to research, applications advances 3SPIE DSS provides venue for collaboration vital to research, applications advances 4
... ALEXANDRIA, Va., Dec. 9 First Coast Service Options ... in Medicare reimbursement solutions, to support a new Medicare ... Medicaid Services (CMS). , , ... disputes beginning Jan. 1, 2009 between health care providers ...
... Delcath Systems, Inc. (Nasdaq: DCTH ) today announced ... Directors. Dr. Stoll is Executive Chairman of Cortex Pharmaceuticals, Inc. ... treatment of central nervous system disorders. , ... , Prior to joining Cortex, Dr. ...
... CHESHIRE, Conn., Dec. 9 Soliris(R) (eculizumab),a terminal complement ... ), was observed by investigators to reduce blood measures,associated ... PNH. , A ... indicators of,pulmonary artery hypertension (PAH) in patients with paroxysmal ...
Cached Biology Technology:FCSO Selects Burgess as Exclusive Pricing Solution for New Medicare Contract 2Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 2Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 3Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 2Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 3Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 4Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 5Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 6Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 7Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 8
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... the impact of student research on life at American University,s ... Following a 2009 study at American University,s main dining ... dishes used when trays were removed, trays have mostly gone ... the first time, a new paper coauthored by AU professor ...
... Houston faculty members have been named Charter Fellows of ... contributions to scientific and technological innovation. UH faculty ... Paul Chu, a physics professor and chief scientist of ... Dan Luss, a professor in chemical and biomedical engineering, ...
... (H2S) may play a wide-ranging role in staving off ... print in the journal Molecular and Cellular Biology ... explores the compound,s plethora of potential anti-aging pathways. ... important endogenous signaling molecule because of its significant effects ...
Cached Biology News:Going trayless study shows student impact 2Going trayless study shows student impact 3National Academy of Inventors honors 3 University of Houston professors 2National Academy of Inventors honors 3 University of Houston professors 3Hydrogen sulfide: The next anti-aging agent? 2
... Diluted Antiserum for RIA, Host: Rabbit ... Immunology Products, Host: Rabbit Antigen ... peptide and 1 2 ... (rat) (H-9295) and ([ 1 2 ...
...
RatTRAPTM Assay is a solid-phase immunofixed enzyme activity assay for the determination of osteoclast-derived TRACP 5b activity in rat serum....
... EnzChek Pyrophosphate Detection Kit,provides a fast, ... the inorganic pyrophosphate (PPi ) produced,by ... as DNA and,RNA polymerizations, cyclic AMP ... the enzymatic activation of fatty acids ...
Biology Products: